Diagnostics

  • Close-Up Of Pipette Dripping Chemical In Test Tube At Laboratory
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Genetic tests come under scrutiny in Trump administration’s fraud crackdown

    As the Centers for Medicare and Medicaid Services calls for public feedback on how to stop lab test fraud, experts say a tailored regulatory strategy will be key to avoid stifling innovation.

    By • March 12, 2026
  • A sign announces the company name at Agilent's headquarters building in Santa Clara, California.
    Image attribution tooltip
    Permission granted by Agilent
    Image attribution tooltip

    Agilent to buy Biocare Medical for $950M

    Biocare’s strong growth in immunohistochemistry is expected to strengthen Agilent’s ability to develop new in vitro diagnostic antibodies.

    By • March 9, 2026
  • Intuitive Surgical's da Vinci 5 robotic system. Explore the Trendline➔
    Image attribution tooltip
    Courtesy of Intuitive Surgical
    Image attribution tooltip
    Trendline

    Top 5 stories from MedTech Dive

    From the top medtech trends to watch in 2026 to haphazard layoffs at the Food and Drug Administration and the evolving use of AI in the medtech sector, here is a collection of top stories from MedTech Dive.

    By MedTech Dive staff
  • A picture of the exterior of a Labcorp building.
    Image attribution tooltip
    Courtesy of Labcorp
    Image attribution tooltip

    Labcorp expands PathAI pact to roll out digital pathology platform in US

    Labcorp’s pathologists will use the software to review, interpret and manage digital images of slides for primary diagnosis.

    By • Feb. 25, 2026
  • A lab technician runs Guardant Health's Shield blood test for colorectal cancer screening in a lab.
    Image attribution tooltip
    Courtesy of Business Wire
    Image attribution tooltip

    Guardant buys MetaSight for $59M upfront to acquire blood test tech

    MetaSight uses metabolomics, lipidomics and proteomics mass spectrometry technologies to develop tests for specific diseases, including conditions outside of oncology.

    By • Feb. 23, 2026
  • Test tube blood
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Grail’s multi-cancer early detection test misses study goal

    Shares in the company lost about half their value in Friday trading after the clinical trial failed to demonstrate a statistically significant reduction in Stage III and IV cancers.

    By • Feb. 20, 2026
  • A person stands in front of the screen of a machine on wheels, near a sign that says "GE HealthCare"
    Image attribution tooltip
    Stringer via Getty Images
    Image attribution tooltip

    GE HealthCare, BARDA ink $35M expansion to AI-enabled imaging deal

    The jointly funded project positions GE HealthCare to develop ultrasound technologies that non-expert users can operate.

    By • Feb. 18, 2026
  • A picture of Masimo's headquarters building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Danaher to buy Masimo for $9.9B to boost diagnostics portfolio

    Masimo’s board considered other potential partners before determining Danaher was an “ideal fit,” executives at the patient monitoring company said.

    By • Feb. 17, 2026
  • A picture of Siemens Healthineers' headquarters building in Erlangen, Germany.
    Image attribution tooltip
    Courtesy of Siemens Healthineers
    Image attribution tooltip

    Siemens Healthineers, Mayo Clinic partner on neurodegenerative disease, cancer

    An expanded collaboration between the two organizations will focus on prostate cancer and metastatic liver tumors, in addition to certain neurological disorders.

    By • Feb. 13, 2026
  • Image attribution tooltip
    Justin Sullivan via Getty Images
    Image attribution tooltip

    Labcorp closes takeover of Empire City assets to fuel New York expansion

    The company struck three deals in New York last year as part of its push to acquire hospital and regional testing labs.

    By • Feb. 11, 2026
  • FDA
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    FDA breakthrough program starts FY2026 at steady pace

    Orthopedics was the most active area over the second half of 2025, with the FDA issuing 13 breakthrough designations to devices in the therapeutic area.

    By • Feb. 9, 2026
  • Medicare enrollment form and money.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Genetic testing takes greater share of Medicare Part B test spending: OIG

    Spending on the tests, which analyze genetic material from both people and pathogens, rose 20% year over year in 2024, the analysis found.

    By • Feb. 4, 2026
  • A Grail employee in a white coat works in a lab.
    Image attribution tooltip
    Courtesy of Grail
    Image attribution tooltip

    Grail files for FDA approval of multi-cancer early detection test

    Premarket approval could help the company secure coverage from commercial payers and Medicare.

    By • Feb. 2, 2026
  • Michael Iskra, wearing a navy blue jacket and light blue shirt, smiles in a head shot.
    Image attribution tooltip
    Permission granted by Cleveland Diagnostics
    Image attribution tooltip

    Cleveland Diagnostics names Michael Iskra CEO

    Iskra will help Cleveland Diagnostics scale up commercial adoption of its IsoPSA blood-based test that analyzes the structure of protein biomarkers for prostate cancer signals.

    By • Jan. 29, 2026
  • Becton Dickinson logo
    Image attribution tooltip
    Permission granted by Becton Dickinson
    Image attribution tooltip

    BD, Waters set completion date for $17.5B biosciences and diagnostics merger

    With Waters stockholders voting to issue shares, the companies are targeting a Feb. 9 close date for the deal.

    By • Jan. 28, 2026
  • Modern glass and metal office building with a reflective blue-tinted facade, set against a clear blue sky. In the foreground, a large black and white sign reads “Abbott” with the company’s stylized logo and the number “645.” The area has neatly cut grass and a few small trees.
    Image attribution tooltip
    Alamy
    Image attribution tooltip

    Abbott posts Q4 sales below expectations

    Pricing challenges in Abbott’s nutrition business and lower than expected sales of continuous glucose monitors drove down the company’s shares.

    By • Jan. 22, 2026
  • A close-up image of an Nvidia chip on a computer motherboard.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Trump issues 25% tariffs on narrow range of semiconductors

    The levies, effective Jan. 15, do not cover products used for data centers and consumer applications, per a proclamation signed Wednesday.

    By Antone Gonsalves , Phil Neuffer • Jan. 15, 2026
  • A sign that says Illumina is on a curb in front of red brick buildings.
    Image attribution tooltip
    Courtesy of Illumina
    Image attribution tooltip

    Illumina names former NIH genomics director as chief medical officer

    The company unveiled the appointment alongside news of the departure of its chief commercial officer.

    By • Jan. 12, 2026
  • A person wearing scrubs, a mask and a cap looks at a screen with images.
    Image attribution tooltip
    Courtesy of Philips
    Image attribution tooltip

    Philips to acquire SpectraWAVE

    SpectraWAVE makes technologies to help diagnose and guide treatment decisions for coronary artery disease.

    By • Dec. 15, 2025
  • An illustration of DNA against a blue abstract background
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Natera acquires Foresight Diagnostics for up to $450M

    Foresight’s technology will be integrated into Natera’s Signatera platform and is expected to be launched for clinical use in 2026.

    By • Dec. 10, 2025
  • A person covered by a blue sheet lays flat under a rectangular, white tube.
    Image attribution tooltip
    Courtesy of Mayo Clinic
    Image attribution tooltip

    GE HealthCare, Mayo Clinic expand partnership around radiology research

    Ben Newton, GE HealthCare’s global head of oncology, said the partnership will shift radiation therapy from a “one-size-fits-all” approach to a personalized method.

    By • Dec. 9, 2025
  • The building features a modern glass façade with the Nasdaq logo prominently displayed. Surrounding the structure are other commercial buildings and digital billboards, which are characteristic of the vibrant Times Square environment.
    Image attribution tooltip
    Alamy
    Image attribution tooltip

    Freenome inks deals to list stock and raise $330M

    The company plans to use the proceeds to expand its commercial and data infrastructure to support the launch of multiple blood-based cancer detection tests.

    By • Dec. 8, 2025
  • Two young scientists conducting medical research in a laboratory.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    CHS sells lab assets to Labcorp for $194M

    The deal, first announced in July, includes outreach laboratory services in 13 states. CHS will continue to operate inpatient and emergency department labs.

    By Susanna Vogel • Dec. 4, 2025
  • A warehouse with rows of packages
    Image attribution tooltip
    Courtesy of Medline
    Image attribution tooltip

    PitchBook: AI tuck-in deals to drive M&A acceleration in 2026

    Buyers will focus on “tuck-ins that add AI or data-driven capabilities or can meaningfully improve scale against emerging competitors,” the analysts said.

    By • Dec. 3, 2025
  • A Cleveland Diagnostics lab technician wearing a white coat and blue gloves analyzes results from an IsoPSA sample in a lab.
    Image attribution tooltip
    Permission granted by Cleveland Diagnostics
    Image attribution tooltip

    Cleveland Diagnostics wins FDA nod for prostate cancer test

    The IsoPSA test is intended to help assess whether patients with elevated PSA levels should go on to receive a biopsy procedure.

    By • Dec. 2, 2025
  • Senior Research Associate Tanya Quint loads one of the instruments used to run Exact Sciences' Cologuard test at the company's headquarters in Madison, Wis. (Photo: Business Wire)
    Image attribution tooltip
    Courtesy of Business Wire/Exact Sciences
    Image attribution tooltip

    Abbott’s $21B Exact Sciences buy reveals future strategy

    The proposed deal, the biggest under CEO Robert Ford’s tenure, would allow Abbott to enter a large, new market for cancer testing. 

    By • Nov. 21, 2025